DaVita (DVA) Stock Analysis & Winston Score

DaVita runs a large network of kidney dialysis clinics across the United States. Dialysis is a medical treatment that cleans the blood of patients whose kidneys no longer work properly. DaVita is one of the two dominant dialysis providers in the U.S., alongside Fresenius, and together they serve the majority of American dialysis patients. The company earns money by charging for each dialysis treatment, which patients typically need three times per week for the rest of their lives. Most payments come from Medicare and Medicaid, meaning the U.S. government is DaVita's largest customer. DaVita also operates some international clinics, but the U.S. is by far its core market. Its main competitive advantage is scale — thousands of conveniently located clinics and long-term patient relationships create steady, recurring revenue. The biggest risk is government reimbursement rates, since any cuts to Medicare dialysis payments would directly reduce DaVita's income.